SCHEDULE 13G/A: Frazier Funds and Affiliates Disclose Amended Passive Stake in AnaptysBio, Inc.

Frazier Life Sciences and Healthcare funds, along with several key individuals, have filed an amended Schedule 13G/A disclosing their passive beneficial ownership in AnaptysBio, Inc. as of December 31, 2024.

Summary

• Frazier Life Sciences Public Fund, L.P. and its related entities (FHMLSP, L.P. and FHMLSP, L.L.C.) collectively beneficially own 612,503 shares of AnaptysBio, Inc. Common Stock, representing 2.0% of the class.
• Frazier Life Sciences Public Overage Fund, L.P. and its related entities (FHMLSP Overage, L.P. and FHMLSP Overage, L.L.C.) collectively beneficially own 77,778 shares, representing 0.3% of the class.
• Frazier Life Sciences X, L.P. and its related entities (FHMLS X, L.P. and FHMLS X, L.L.C.) collectively beneficially own 77,014 shares, representing 0.3% of the class.
• Frazier Life Sciences XI, L.P. and its related entities (FHMLS XI, L.P. and FHMLS XI, L.L.C.) collectively beneficially own 165,521 shares, representing 0.5% of the class.
• Frazier Healthcare VII, L.P. and Frazier Healthcare VII-A, L.P., along with their related entities (FHM VII, L.P. and FHM VII, L.L.C.), collectively beneficially own 640,903 shares (498,769 from FH VII and 142,134 from FH VII-A), representing 2.1% of the class.
• James N. Topper beneficially owns an aggregate of 1,655,295 shares, comprising 80,812 sole shares and 1,574,483 shared shares, representing 5.4% of the class.
• Patrick J. Heron beneficially owns an aggregate of 1,583,593 shares, comprising 9,110 sole shares and 1,574,483 shared shares, representing 5.2% of the class.
• Albert Cha and James Brush each beneficially own 690,281 shares (2.3%), derived from their shared voting and investment power over shares held by Frazier Life Sciences Public Fund, L.P. and Frazier Life Sciences Public Overage Fund, L.P.
• Daniel Estes beneficially owns 165,521 shares (0.5%), derived from shared voting and investment power over shares held by Frazier Life Sciences XI, L.P.
• Alan Frazier, Nader Naini, Nathan Every, and Brian Morfitt each beneficially own shares derived from shared voting and investment power over shares held by Frazier Healthcare VII, L.P. and Frazier Healthcare VII-A, L.P., with Alan Frazier and Nader Naini each owning 640,903 shares (2.1%), Nathan Every owning 645,526 shares (2.1%), and Brian Morfitt owning 646,272 shares (2.1%).
• The percentages of ownership are calculated based on 30,428,682 shares of AnaptysBio, Inc. Common Stock outstanding as of October 31, 2024, as reported in the Issuer's Form 10-Q filed on November 5, 2024.
• The filing is an Amendment No. 1 to a Schedule 13G, indicating a passive investment purpose and no intent to change or influence control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the issuer's performance or prospects. It is a neutral regulatory filing.

Future Outlook

NA

Industry Context

This filing is a standard disclosure of passive beneficial ownership by institutional investors in a publicly traded biotechnology company. It reflects a continued or adjusted investment position by Frazier funds, which are active in the life sciences and healthcare sectors. Such filings are common for investment firms managing portfolios in specific industries.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant passive ownership stakes by institutional investors and key individuals associated with Frazier funds, which can influence market perception and liquidity.

Key Dates

Keywords

AnaptysBio Inc., Frazier Life Sciences, Frazier Healthcare, Schedule 13G/A, Beneficial Ownership, SEC Filing, Common Stock, Passive Investment, Institutional Ownership, Biotechnology